The updated ESC #HeartFailure guidelines #ESCCongress @escardio

Research letter : Undiagnosed #CKD , Outcomes, and #Finerenone in #HeartFailure (#FINEARTS-HF Trial ) jamanetwork.com/journals/jam… @JAMACardio @mvaduganathan

Polypharmacy and Drug-Drug Interactions Among Older Adults jamanetwork.com/journals/jam… @JAMA_current

💡New Evidence in Heart Failure: 2026 Update, see comprehensive UPDATE @ ow.ly/7YhP50ZRltV @EJHFEiC @AmrAbdin10 @GiuseppeGalati_ @HanCardiomd @EJHFEiC @JanBiegus @ppponikowski #HFA_ESC @hvanspall @FudimMarat @gcfmd @MarcoMetra @GianluSava

Now in @CircHF by #HFC member @FudimMarat et al. This case report shows position-dependent RV hemodynamics in an LVAD patient, while implantable IVC monitoring closely tracks right-atrial pressure. ahajournals.org/doi/10.1161/…

#MRA-induced #eGFR decline—causes, consequences, and context Therapeutic inertia: a consequence of misinterpretation and what are the remaining uncertainties academic.oup.com/eurjhf/arti… @ESC_Journals #EJHF

Interpreting potential benefit on secondary outcomes when a trial fails to meet its primary endpoint academic.oup.com/eurjhf/adva… @JavedButler1 @FaiezZANNAD @EJHFEiC #EJHF

#ABYSS + #SMART-DECISION pooled analysis 6,238 stable post-MI patients, #LVEF ≥40%, no HF. 📍Primary endpoint: 17.2% vs 15.9%; HR 1.09 (95% CI 0.97–1.24) — non-inferiority not demonstrated.
📍Death/MI/HF hospitalization: 6.5% vs 6.4%; HR 1.01 (0.83–1.23) — non-inferior. thelancet.com/journals/lance… @TheLancet

Efficacy and Safety of #Semaglutide According to Frailty Status A Post Hoc Analysis of the #SELECT Trial jamanetwork.com/journals/jam… @JAMA_current @JAMACardio

@LaskerFDN awards: Celebrating scientists who dedicated their lives turning discovery into hope. From decoding sleep/orexin biology,➡️advancing transformative therapy for hemophilia A,➡️ @realmikefox turning dx into a global movement for Parkinson’s research w/@NobelPrize winners

Out now in #EJHF from #HFC members @JavedButler1 @LindenfeldJoann @robmentz @coconnormd et al. This VICTOR analysis evaluates whether the effect of vericiguat in ambulatory HFrEF varies by background GDMT class, dose, or overall treatment intensity. academic.oup.com/eurjhf/adva…

🗞️ Mortality benefit and lifetime survival gains with vericiguat in HFrEF: Bayesian and actuarial analyses of the VICTOR trial @ESC_Journals @GiuseppeGalati_ @AmrAbdin10 @HanCardiomd bit.ly/4cXxAlL

Timing-specific factors associated with early, intermediate, and late readmission after heart failure hospitalization ow.ly/QxsZ50ZPol3 @EJHFEiC @AmrAbdin10 @GiuseppeGalati_ @HanCardiomd @EJHFEiC @JanBiegus @ppponikowski #HFA_ESC @hvanspall @FudimMarat @gcfmd @MarcoMetra @GianluSava

Now in @JACCJournals from #HFC members @DukeHFDoc @scottdsolomon, et al. This analysis from GALACTIC-HF examines whether the treatment effect of omecamtiv mecarbil varies across baseline risk, defined by the PREDICT-HF score, in outpatients with HFrEF. jacc.org/doi/10.1016/j.jchf.…

European Society of Cardiology #Congress2026 @escardio in Munich was bigger than most cities' entire medical communities — 30,000+ attendees, one conference. A few highlights from my time there: 🌟 In the age or #AI and #Precision medicine, 2026 ACC/AHA Clinical Guidelines have recognized high #polygenicriskscore or PRS as a heart disease risk enhancer. 🌟 In one of the opening day sessions I shared data from #KaiserPermanente GERA multi-ethnic cohort (n=63,070), that how incorporating CAD PRS into clinical risk assessment improves accuracy of CAD risk prediction and can help guide therapy intensification. 🌟 #Genes are not #Destiny. I shared data that having favorable lifestyle can mitigate risk despite high genetic predisposition. 🌟 The American College of Cardiology #Presidential Reception, hosted by @Drroxmehran, was easily one of the best rooms of the congress — great conversations, great energy. Reconnected with colleagues and met cardiology leaders from every corner of the globe. #Science #CardiovascularCare #Innovation @jgharoldmd, @Hragy, @DrMarthaGulati @drmalissawood @AnastasiaSMihai @Jcontreras75 @aboutKP @KPDOR

Inspiring night @TIME 100 Health Leadership Forum. @oliviamunn on breast health. @melindagates on ♀️’s healthy aging. @mariashriver on ♀️’s brain health. @realmikefox asked by TIME’s @AliceParkNY what he wants to be remembered for: work & advocacy toward tackling Parkinson’s.

Type 2 DM and #CKD combinations in heart failure across the EF spectrum: clinical associations, medication use, and cause-specific outcomes: a contemporary, real-world analysis of the Swedish HF Registry academic.oup.com/eurjhf/adva… #EJHF @HanCardiomd @AmrAbdin10 @GiuseppeGalati_

Hierarchical composite endpoints in heart failure trials: clarity or confusion? #HeartFailure @EJHFEiC @ESC_Journals #EJHF

Rethinking Tricuspid Regurgitation in Transthyretin Amyloid #Cardiomyopathy #TricuspidRegurgitation #ATTR @JAMACardio @JAMA_current

Timing-specific factors associated with early, intermediate, and late readmission after heart failure hospitalization see@ ow.ly/ivTa50ZMq7e @EJHFEiC @AmrAbdin10 @GiuseppeGalati_ @HanCardiomd @EJHFEiC @JanBiegus @ppponikowski #HFA_ESC @hvanspall @FudimMarat @gcfmd @MarcoMetra @GianluSava

Beyond procedural success after #TAVI: is multi-pillar heart failure therapy the next frontier? academic.oup.com/eurjhf/adva… @ESC_Journals @EJHFEiC